Under the agreement, Eli Lilly will continue to market tirzepatide under brand name Mounjaro, while Cipla will have the ...

Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...

Eli Lilly's launch of Mounjaro in India in March 2025 was the first step of Tirzepatide in the country. In June 2025, the ...

Eli Lilly's rival Novo Nordisk plans to retail both Ozempic and Wegovy in India as diabetes and weight-loss drugs, ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

Eli Lilly has signed a licensing deal with Cipla to market its blockbuster weight-loss drug under the brand name Yurpeak in ...

Indian drugmaker Cipla Limited has entered into a strategic marketing and distribution agreement with US pharma major Eli ...

Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Per the agreement, the Indianapolis-based drugmaker will continue to manufacture the drug, which India-based Cipla will sell under a new brand name.

Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand ...